论文部分内容阅读
对126例T2DM患者测定血清Hcy、腓总神经、正中神经、腓肠神经的运动或感觉传导速度,据此分为无周围神经病变组(A组)58例和有周围神经病变组(B组)68例,50例正常对照组。B组给予甲钴胺进行干预治疗。结果A、B组血清Hcy水平高于正常对照组(P<0.05),B组更明显(P<0.05)。甲钴胺干预4周后,血清Hcy水平明显下降(P<0.05)。运动和感觉传导速度治疗后较治疗前有明显改善(P<0.05)。结论高Hcy血症是T2DM的重要危险因素,甲钴胺可显著降低DPN患者血清高Hcy水平,提高DPN患者神经传导速度,从而改善临床症状。
In 126 T2DM patients, the motor or sensory conduction velocity of serum Hcy, common peroneal nerve, median nerve and sural nerve were measured. According to the result, 58 cases of peripheral neuropathy group (A group) and peripheral nerve lesion group (B group) ) 68 cases, 50 cases of normal control group. Group B was given mecobalamin for intervention. Results The level of Hcy in group A and group B was higher than that in control group (P <0.05), and group B was more obvious (P <0.05). Mecobalamin intervention 4 weeks after the serum Hcy levels were significantly decreased (P <0.05). Movement and sensory conduction velocity were significantly improved after treatment (P <0.05). Conclusions Hyperhomocysteinemia is an important risk factor for T2DM. Mecobalamin can significantly reduce the serum homocysteine level in DPN patients and improve the nerve conduction velocity in patients with DPN, thus improving the clinical symptoms.